Technology News and Research

RSS

HELM purchases 30% shareholding in Amarin

Effective September 28th, 2010, Hamburg based HELM AG has purchased a 30% shareholding in Amarin Technologies S.A. a privately owned pharmaceutical development company in Buenos Aires, Argentina.

15 Dec 2010

joimax to present C-Camsource HD Twister for endoscopic spinal surgery at 5th German Spine Congress

The 5th German Spine Congress (5. Jahrestagung der Deutschen Wirbelsaulengesellschaft (DWG)) will take place from 16 to 18 December 2010 at the Congress Centre in Bremen. joimax(R) is proud to present the innovative HD 5-in-1 complete system at their booth no.20: The C-Camsource(R)HD Twister offers state-of-the-art HD technology and works with both the joimax(R) HD endoscopes and HD flat screens producing an extremely precise and sharp picture and video imaging for endoscopic spinal surgery.

15 Dec 2010

RPCI forms Photolitec to develop photosensitizing compounds used in photodynamic therapy

Roswell Park Cancer Institute (RPCI) on December 13, 2010, announced the formation of Photolitec, LLC, a new life-sciences company at RPCI that will develop photosensitizing compounds used in photodynamic therapy (PDT). PDT is an innovative cancer treatment pioneered at RPCI by scientist Thomas J. Dougherty, Chief Emeritus of the Institute's Photodynamic Therapy Center.

15 Dec 2010

New online tools allow parents with autistic children to enjoy holiday season

Rethink Autism, an educational technology company that produces online research-based treatment tools for parents and professionals, offers some suggestions and a free online set of video tips to help families address some of these challenges and enjoy the holidays.

15 Dec 2010

Domainex wins 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award

Domainex Ltd, the leading UK-based drug discovery CRO, has won the 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award. This Award was made in recognition of Domainex's proactive work on promoting academic-industry collaborations, and was adjudicated by leading representatives of the biotechnology and pharmaceutical industries.

From Domainex 15 Dec 2010

CTT, Bayer sign Research and License Option Agreement

Cancer Targeted Technology (CTT), a Seattle-based biotechnology firm focusing on small molecule cancer enzyme inhibitors for the generation of novel diagnostics and therapeutics, today announced that it has signed a Research and License Option Agreement with Bayer Pharma AG, Germany. Under the agreement, CTT will work with Bayer to optimize a novel PET imaging agent based on its unique inhibitor scaffold that recognizes a validated cancer enzyme biomarker.

15 Dec 2010

Anoles key to medically applicable regeneration?

Anolis lizards first entered Arizona State University biologist Kenro Kusumi's life in 1980 when, as a member of a junior curator program, he recorded in his field notebook that he had found an Anolis egg on a field trip. Kusumi still has those notes, along with other memorabilia that document the influence that both his early life and more recent experiences have had on his current pursuits in developmental biology.

15 Dec 2010

Plasma technology safe, effective alternative to antibiotics to treat multi-drug resistant infections

Cold plasma jets could be a safe, effective alternative to antibiotics to treat multi-drug resistant infections, says a study published this week in the January issue of the Journal of Medical Microbiology.

15 Dec 2010

Positive results from Creabilis CT327 Phase IIa study in atopic dermatitis

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, announced positive results in the Phase IIa study of its lead product CT327 in atopic dermatitis.

15 Dec 2010

AzTe and Zcube: Innovative treatment of chronic respiratory diseases

Zcube, Srl, the research venture of Italian pharmaceutical company Zambon Co., SpA, and Arizona Technology Enterprises (AzTE), the technology venturing arm of Arizona State University, have entered into a licensing agreement that will allow Zcube to use ASU technology to develop and commercialize next-generation medical devices that can better monitor and treat chronic respiratory diseases like asthma.

15 Dec 2010

CMS increases reimbursement rate for Cylex's immune cell function assay by 267%

Cylex Incorporated® today announced that the Centers for Medicare and Medicaid Services (CMS) nearly tripled the reimbursement for ImmuKnow®, the immune cell function assay FDA-cleared for the detection of cell-mediated immune response in populations undergoing immunosuppressive therapy for organ transplant. This significant increase was granted in a time when the overall CMS clinical fee schedule experienced a comprehensive decrease in laboratory reimbursement rates.

15 Dec 2010

Researchers develop synthetic circuits to detect changes in state of health

Using yeast cells, a group of researchers at the University of Gothenburg, Sweden, has taken a groundbreaking step towards being able to build complex systems in the future where the body's own cells help to keep us healthy.

15 Dec 2010

Positive results from large, multi-center Canadian trial with On-X Prosthetic Heart Valve

On-X® Life Technologies, Inc., today announced the publication of results of a large, prospective multi-center Canadian trial with the On-X® Prosthetic Heart Valve in the November issue of The Journal of Thoracic and Cardiovascular Surgery.1 According to the results of the report, "The On-X mechanical prosthesis provides favorable intermediate-term results with regard to major thromboembolism, hemorrhage and composites of valve-related complications."

15 Dec 2010

DSM licenses c-LEcta's alcohol dehydrogenases for enzyme screening programs

DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, today announces a license agreement with c-LEcta GmbH for proprietary screening technology.

15 Dec 2010

Cell Biosciences receives US Patent for NanoPro assay technology

Cell Biosciences, Inc. today announced the issuance of Patent No. 7,846,676 for "Methods and Devices for Analyte Detection" by the United States Patent and Trademark Office.

15 Dec 2010

Reuters looks at cost-effectiveness of pursuing malaria vaccine, eradication

Reuters examines the effort to create an effective malaria vaccine and asks: "[I]s the vaccine - and the global health community's aim of completely eradicating a disease that kills a child every 45 seconds - really worth the money?"

15 Dec 2010

Myotec, Hybrid merge to form PsiOxus Therapeutics

Myotec Therapeutics, Ltd. and Hybrid BioSystems, Ltd. today announced their merger to form PsiOxus Therapeutics, Ltd. (PsiOxus), a new, development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer and wasting diseases. PsiOxus, which will be led by CEO Dr. John Beadle, boasts a combined pipeline of phase I and II clinical stage assets.

15 Dec 2010

Case study sheds light on pathological course of Alzheimer's disease

A case study from the Swedish medical university Karolinska Institutet sheds light on the pathological course of Alzheimer's disease. The brain of the first Alzheimer's patient to display amyloids demonstrable with a PET scanner has been studied, both during progression of the disease and after death.

15 Dec 2010

Sharing of scientific data could benefit cancer research

The sharing of scientific data in increasingly open ways could benefit cancer research and thus patients, according to a paper published in the peer-reviewed journal ecancermedicalscience.

15 Dec 2010

Alcon board approves merger agreement with Novartis

Alcon, Inc. announced today that its board of directors approved a merger agreement with Novartis AG, whereby Novartis will pay a total merger consideration valued at $168 per share for the Alcon shares it does not currently own. Under the terms of the deal, the merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.

15 Dec 2010